Treatment of chronic Hepatitis C in the age of direct-acting antivirals with emphasis on first generation inhibitors of HCV NS3/4A protease

被引：0

作者：

Truesdale A.E. ^{[1
,2
]}

Everson G.T. ^{[1
,2
]}

机构：

[1] Transplant Hepatology, University of Colorado Denver, Aurora, CO 80045, 1635 N. Aurora Court

[2] Aurora, CO 80045, 1635 N. Aurora Court

来源：

Current Hepatitis Reports | 2011年 / 10卷 / 3期

关键词：

Boceprevir; Chronic hepatitis C; Direct-acting antivirals; Hepatitis C virus; NS3/4A protease; NS5A protein; NS5B polymerase; Peginterferon; Ribavirin; Telaprevir; Treatment algorithms; Viral resistance;

D O I：

10.1007/s11901-011-0107-1

中图分类号：

学科分类号：

摘要：

The past standard-of-care (SOC) for treatment of the chronic hepatitis C virus (HCV) was the combination of peginterferon with ribavirin (P+R). Sustained virologic response (SVR) for patients with HCV, genotype 1, was less than 50%. The new emerging SOC, Triple Therapy, using direct-acting antivirals (DAAs) with P+R will improve SVR for HCV genotype 1 infection to approximately 75%. Telaprevir and boceprevir are inhibitors of HCV NS3/4A serine protease and will be the first DAAs for treatment of patients with chronic hepatitis C. The treatment provider must effectively manage dosage and adherence to the regimen to avoid emergence of resistant variants of HCV. Close monitoring of patients, awareness of drug interactions, management of known telaprevir and boceprevir side effects, and strategies for reduction or discontinuation of individual drugs in the treatment regimen will be critical to ultimate success of triple therapy. © Springer Science+Business Media, LLC 2011.

引用

页码：204 / 213

页数：9

共 37 条

[1]

Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., Ling M., Albrecht J., Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C, Gastroenterology, 122, 5, pp. 1303-1313, (2002)

[2]

Bruno S., Stroffolini T., Colombo M., Bollani S., Benvegnu L., Mazzella G., Ascione A., Santantonio T., Piccinino F., Andreone P., Mangia A., Gaeta G.B., Persico M., Fagiuoli S., Almasio P.L., Sustained virological response to interferon-α is with improved outcome in HCV-related cirrhosis: A retrospective study, Hepatology, 45, 3, pp. 579-587, (2007)

[3]

Camma C., Di Bona D., Schepis F., Heathcote J., Zeuzem S., Pockros P.J., Marceliln P., Balart L., Alberti A., Craxi A., Effect of Peginterferon Alfa-2a on Liver Histology in Chronic Hepatitis C: A Meta-analysis of Individual Patient Data, Hepatology, 39, 2, pp. 333-342, (2004)

[4]

George S.L., Bacon B.R., Brunt E.M., Et al., Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients, Hepatology, 49, pp. 729-738, (2009)

[5]

Veldt B.J., Heathcote E.J., Wedemeyer H., Reichen J., Hofmann W.P., Zeuzem S., Manns M.P., Hansen B.E., Schalm S.W., Janssen H.L.A., Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis, Annals of Internal Medicine, 147, 10, pp. 677-684, (2007)

[6]

Morgan T.R., Ghany M.G., Kim H.Y., Et al., Outcome of sustained virological responders with histologically advanced chronic hepatitis C, Hepatology, 52, pp. 833-844

[7]

Fried M.W., Shiffman M.L., Reddy K.R., Et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med., 347, pp. 975-982, (2002)

[8]

Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M.-H., Albrecht J.K., Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial, Lancet, 358, 9286, pp. 958-965, (2001)

[9]

McHutchison J.G., Everson G.T., Gordon S.C., Et al., Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection, N Engl J Med, 360, pp. 1827-1838, (2009)

[10]

Hezode C., Forestier N., Dusheiko G., Et al., Telaprevir and peginterferon with or without ribavirin for chronic HCV infection, N Engl J Med, 360, pp. 1839-1850, (2009)

← 1 2 3 4 →